| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-04-18 | RHB-105 (amoxicillin, rifabutin and omeprazole) | H. pylori infection | 3 | RedHill Biopharma (Israel) | Infectious diseases |
| 2016-04-18 | Zebinix® (eslicarbazepine acetate) | newly diagnosed partial-onset seizures | 3 | Eisai (Japan) Bial (Portugal) | CNS diseases - Neurological diseases |
| 2016-04-18 | IPH4301 | preclinical | Innate Pharma (France) | Cancer - Oncology | |
| 2016-04-18 | CD73 checkpoint inhibitor antibodies | preclinical | Innate Pharma (France) | Cancer - Oncology | |
| 2016-04-18 | monalizumab (IPH2201) and durvalumab | preclinical | Innate Pharma (France) | Cancer - Oncology | |
| 2016-04-18 | Reolysin® (pelareorep - human reovirus type 3 Dearing strain) | multiple myeloma | preclinical | Oncolytics Biotech (Canada) | Cancer - Oncology |
| 2016-04-18 | Reolysin® (pelareorep - human reovirus type 3 Dearing strain) | colorectal cancer | preclinical | Oncolytics Biotech (Canada) | Cancer - Oncology |
| 2016-04-18 | panel of blood-based DNA methylation biomarkers | lung cancer | Epigenomics (Germany - USA) | Cancer - Oncology - Diagnostic | |
| 2016-04-18 | GSK3196165 /MOR103 | inflammatory hand osteoarthritis | 2 | GSK (UK) | Inflammatory diseases - Rheumatic diseases |
| 2016-04-18 | labetuzumab govitecan (IMMU-130) | metastatic colorectal cancer | 2 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2016-04-17 | Halaven® (eribulin) | soft tissue sarcoma | preclinical | Eisai (Japan) | Cancer - Oncology |
| 2016-04-17 | GS-4997 | NASH (non-alcoholic steatohepatitis) | preclinical | Gilead Sciences (USA - CA) | Liver diseases - Hepatic diseases |
| 2016-04-17 | talazoparib | heavily pre-treated non-BRCA-mutated ovarian cancer patients | 1 | Medivation (USA - CA) | Cancer - Oncology |
| 2016-04-16 | sofosbuvir and velpatasvir | patients with HCV genotype 1-6 who are co-infected with HIV | 3 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2016-04-16 | sofosbuvir, velpatasvir (GS-5816) and voxilaprevir (GS-9857) | chronic hepatitis C virus infection | 2 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2016-04-16 | simtuzumab | NASH (non-alcoholic steatohepatitis), primary sclerosing cholangitis (PSC) | 2 | Gilead Sciences (USA - CA) | Liver diseases - Hepatic diseases |
| 2016-04-16 | GS-9674 | NASH (non-alcoholic steatohepatitis) | preclinical | Gilead Sciences (USA - CA) | Liver diseases - Hepatic diseases |
| 2016-04-13 | MIS416 | secondary progressive multiple sclerosis | 2 | Innate Immunotherapeutics (Australia) | Autoimmune diseases - Neurodegenerative diseases |
| 2016-04-12 | WT1-TCR T cell therapy | myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) | 1-2 | Cell and Gene Therapy Catapult (UK) Imperial Innovations (UK) University College London Business (UK) | Cancer - Oncology |
| 2016-04-12 | APD371 | pain | 1b | Arena Pharmaceuticals (USA - CA) | CNS diseases |
